Drug Shortage Prevention Act H.R. 3839
Ask your Representatives to cosponsor H.R. 3839 today!
In the spring of 2011, a shortage of ADHD generic and brand name medications began to emerge in the United States. In addition to ADHD medications, oncology medications, anesthetics, and nutrition medications also experienced shortages. The causes of the drug shortage crisis are numerous and complex, but what is clear is the impact for those that do not receive ADHD medications is devastating. Reports of employment firings, behavioral, academic, and driving problems have increased (three times higher in teens for car accidents) for individuals living with ADHD that are unable to access their medication.
The Solution: H.R. 3839.
Introduced by Rep. John Carney (D-DE) and Rep. Larry Bucshon (R-IN), the Drug Shortage Prevention Act codifies and expands on an executive order by President Obama back on October 31, 2011, dedicated to addressing drug shortages.
H.R. 3839 streamlines intra-agency communications at the Food and Drug Administration (FDA), and communications among the FDA, manufacturers, distributors, providers, and patients. The bill also mandates expedited review of drugs that are vulnerable to shortage in order to prevent shortages in the first place, and it requires the FDA to use a more refined regulatory process that addresses manufacturing problems without instigating drug shortages.